Sweet's syndrome: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
| Line 26: | Line 26: | ||
** Usually upper extremities > lower extremities, with asymmetrical distribution | ** Usually upper extremities > lower extremities, with asymmetrical distribution | ||
* Extracutaneous disease: neutrophilic infiltration of organ systems | * Extracutaneous disease: neutrophilic infiltration of organ systems | ||
** Ocular infiltration (most common): | ** Ocular infiltration (most common): [[conjunctivitis]], [[scleritis]], keratitis, [[iritis]] | ||
** Muscular system: arthralgias, arthritis, myalgia | ** Muscular system: [[arthralgias]], [[arthritis]], [[myalgia]] | ||
** Less commonly CNS, cardiovascular system, pulmonary system, liver, intestines, kidneys, bones | ** Less commonly CNS, cardiovascular system, pulmonary system, liver, intestines, kidneys, bones | ||
* [[Fever]] and leukocytosis | * [[Fever]] and [[leukocytosis]] | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
| Line 58: | Line 58: | ||
==Management== | ==Management== | ||
* Systemic glucocorticoids - prednisone 0.5 - 1.0 mg/kg per day with taper after symptom improvement | * Systemic glucocorticoids - [[prednisone]] 0.5 - 1.0 mg/kg per day with taper after symptom improvement | ||
* Topical and intralesional corticosteroids - limited data, mostly used as adjunct, for mild disease (<5% BSA), or absence of systemic symptoms | * [[topical coritcosteroids|Topical and intralesional corticosteroids]] - limited data, mostly used as adjunct, for mild disease (<5% BSA), or absence of systemic symptoms | ||
* Alternatives agents include colchicine, dapsone, potassium iodide if steroids contraindicated | * Alternatives agents include colchicine, dapsone, potassium iodide if steroids contraindicated | ||
* Referral to dermatology for biopsy | * Referral to dermatology for biopsy | ||
| Line 76: | Line 76: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Dermatology]] | |||
Revision as of 17:52, 25 October 2020
Background
- Acute febrile neutrophilic dermatosis
- Rare skin condition
- Usually affects age 30-60, but can happen in any age group
- Classic Sweet syndrome affects women > men
- Unclear pathologenesis, but possibly factors include hypersensitivity reaction, cytokine dysregulation, or genetic susceptibility
Etiologies
- Classical Sweet syndrome, usually secondary to:
- Infection: Typically 1 to 3 weeks following upper respiratory infection or gastrointestinal infection
- Inflammatory bowel disease: Crohn's disease or ulcerative colitis
- Pregnancy
- Malignancy-associated Sweet syndrome
- Hematologic (~85%), most commonly acute myeloid leukemia
- Solid tumor (~15%), most commonly carcinoma of GU organs, breasts, GI tract
- Drug-induced Sweet syndrome, most commonly granulocyte-colony stimulating factor (G-CSF)
- Typically 2 weeks after drug exposure in patient without prior exposure
- Fever and rash
Clinical Features
Sweet's Syndrome of index finger[1]
- Cutaneous disease
- Painful, edematous, and erythematous papules, plaques, or nodules
- Often exhibit a mamillated surface with significant superficial dermal edema leading to pseudovesicular quality
- Usually upper extremities > lower extremities, with asymmetrical distribution
- Extracutaneous disease: neutrophilic infiltration of organ systems
- Ocular infiltration (most common): conjunctivitis, scleritis, keratitis, iritis
- Muscular system: arthralgias, arthritis, myalgia
- Less commonly CNS, cardiovascular system, pulmonary system, liver, intestines, kidneys, bones
- Fever and leukocytosis
Differential Diagnosis
Evaluation
Workup
- CBC
- leukocytosis with neutrophilia
- anemia (more common in malignancy or drug associated)
- platelet abnormalities (more common in malignancy or drug associated)
- Complete metabolic panel
- Urinalysis
- ESR
- CRP
Diagnosis
Major criteria
- Abrupt onset painful erythematous plaques or nodules
- Histopathological evidence of neutrophilic infiltrate without evidence of leukocyoclastic vasculitis
Minor criteria
- Fever
- Associated malignancy, IBD, pregnancy, preceding URI, preceding GI infection
- Improvement with treatment with systemic steroids
- Abnormal labs (3+ of following): ESR > 20, elevated CRP, leukocytosis, neutrophilic predominance
Management
- Systemic glucocorticoids - prednisone 0.5 - 1.0 mg/kg per day with taper after symptom improvement
- Topical and intralesional corticosteroids - limited data, mostly used as adjunct, for mild disease (<5% BSA), or absence of systemic symptoms
- Alternatives agents include colchicine, dapsone, potassium iodide if steroids contraindicated
- Referral to dermatology for biopsy
- Evaluation for malignancy (if clinically appropriate)
- If other concerning symptoms and no other explanation for diagnosis
Disposition
- Usually outpatient with close dermatology follow up
See Also
External Links
References
- ↑ Cohen, P.R. Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2, 34 (2007). https://doi.org/10.1186/1750-1172-2-34
